Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400
Debt
Debt-to-Equity Ratio0.51
Current Ratio7.20
Quick Ratio7.20
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$210,000.00
Price / Sales1,288.85
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book5.22
Profitability
EPS (Most Recent Fiscal Year)($3.20)
Net Income$-65,320,000.00
Net Margins-31,556.04%
Return on Equity-111.69%
Return on Assets-63.26%
Miscellaneous
Employees64
Outstanding Shares22,350,000
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.11. Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 111.69%. View Selecta Biosciences' Earnings History.
What price target have analysts set for SELB?
3 equities research analysts have issued 12-month price targets for Selecta Biosciences' shares. Their predictions range from $30.00 to $40.00. On average, they anticipate Selecta Biosciences' stock price to reach $35.00 in the next twelve months. View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (5/15/2018)
- 2. Mizuho analysts commented, "We believe the expected phase 3 trial including 6 monthly combination doses of SEL-212 has a high likelihood of success." (4/11/2018)
- 3. Canaccord Genuity analysts commented, "We expect the combination dosing to provide rapid, sustained SUA lowering similarly to what has been seen for the combination SEL-212 + SVP dosing in the ongoing Phase 2 trial." (1/18/2018)
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Wave Life Sciences (WVE), Reata Pharmaceuticals (RETA), Esperion Therapeutics (ESPR), Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Dynavax Technologies (DVAX), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), CytomX Therapeutics (CTMX), MacroGenics (MGNX), OptiNose (OPTN), Assembly Biosciences (ASMB) and Karyopharm Therapeutics (KPTI).
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 49)
- Dr. Werner Cautreels, Pres, CEO & Director (Age 66)
- Dr. John H. Leaman, CFO, Head of Corp. Strategy & Treasurer (Age 45)
- Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 50)
- Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Has Selecta Biosciences been receiving favorable news coverage?
News stories about SELB stock have trended somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.08 on Accern's scale. They also gave media stories about the company an impact score of 44.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Selecta Biosciences' major shareholders?
Selecta Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.82%), JPMorgan Chase & Co. (2.74%), Wasatch Advisors Inc. (0.97%), Artal Group S.A. (0.56%), A.R.T. Advisors LLC (0.27%) and Alps Advisors Inc. (0.13%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Earl Sands, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.
Which major investors are selling Selecta Biosciences stock?
SELB stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc.. Company insiders that have sold Selecta Biosciences company stock in the last year include Amir Nashat, David Siewers, Lloyd P Johnston and Peter Keller. View Insider Buying and Selling for Selecta Biosciences.
Which major investors are buying Selecta Biosciences stock?
SELB stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Artal Group S.A., A.R.T. Advisors LLC, DRW Securities LLC, BlackRock Inc. and Alps Advisors Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Earl Sands, Nanodimension Management Ltd, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $12.11.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $272.89 million and generates $210,000.00 in revenue each year. The company earns $-65,320,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. Selecta Biosciences employs 64 workers across the globe.
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
